Founded in 1943 and headquartered in Barcelona, Spain, Almirall develops and commercializes innovative solutions for dermatological diseases such as psoriasis, actinic keratosis, atopic dermatitis, and acne. With close to 1,800 employees and operations in over 70 countries, Almirall is committed to transforming the lives of patients by providing treatments that address their specific needs. The company's portfolio includes pharmaceutical products developed through extensive research and development efforts, as well as strategic partnerships with global healthcare organizations. Almirall is listed on the Spanish Stock Exchange and has a strong presence in the biopharmaceutical industry.